Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro

Clinical and Experimental Metastasis

Volumn 15, Issue 4, 1997, Pages 447-452

  Go, Yoshinori ^a   Chintala, Shravan K ^a   Rayford, Alan ^a   Gagercas, Evangelin ^a   Ali Osman, Francis ^a   Venkaiah, Boyapati ^a   Sawaya, Raymond ^a   Gokaslan, Ziya ^a   Nicolson, Garth L ^b   Rao, J S ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b Institute for Molecular Medicine   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCNU; Cisplatin; Glioblastoma; Invasion; uPA

Indexed keywords

CARMUSTINE; CISPLATIN; UROKINASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HUMAN; HUMAN CELL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; CISPLATIN; CULTURE MEDIA, SERUM-FREE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 8544230593     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018462507706     Document Type: Article

References (31)

1. Liotta LA, Steeg PS and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: imbalance of positive and negative regulation. Cell, 64, 327-36.
2. Blasi F, Vassalli JD and Danø K, 1987, Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol, 104, 801-4.
3. Danø K, Andreasen PA, Grøndal-Hansen J, et al. 1985, Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 44, 139-266.
4. Saksela O, 1985, Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta, 823, 35-65.
5. Yamamoto M, Sawaya R, Mohanam S, et al. 1994, Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. J Neuro-Oncol, 22, 139-51.
6. Yamamoto M, Sawaya R, Mohanam S, et al. 1994, Expression and localization of urokinase-type plasminogen activator in human astrocytoma in vivo. Cancer Res, 54, 3656-61.
7. Sexauer CL, Khan A, Burger PC, et al. 1985, Cisplatin in recurrent pediatric brain tumors. A POG phase II study. A Pediatric Oncology Group Study. Cancer, 56, 1497-1501.
8. Bertolone SJ, Baum ES, Krivit W, et al. 1985, A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Children's Cancer Study Group. J Neuro-Oncol, 7, 5-11.
9. Edwards MS, Levin VA and Wilson CB, 1980, Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials. Cancer Treat Rep, 64, 1179-205.
10. Kornblith PL and Walker M, 1988, Chemotherapy for malignant gliomas. J Neurosurg, 68, 1-17.
11. Lesser GJ and Grossman S, 1994, The chemotherapy of high-grade astrocytomas. Semin Oncol, 21, 220-35.
12. Deffie AM, Alam T, Seneviratne C, et al. 1988, Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res, 48, 3595-602.
13. Bradley G, Juranka PF and Ling V, 1988, Mechanism of multidrug resistance. Biochim Biophys Acta, 948, 87-128.
14. Kelley SL, Basu A, Teicher BA, et al. 1988, Overexpression of metallothionein confers resistance to anticancer drugs. Science, 241, 1813-15.
15. Kelley SL and Rozencweig M, 1989, Resistance to platinum compounds: mechanisms and beyond. Eur J Cancer Clin Oncol, 25, 1135-40.
16. Andrews PA and Howell SB, 1990, Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-43.
17. Kawai K, Kamatani N, Georges E, et al. 1990, Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cisdiamminedichloroplatinum (II). J Biol Chem, 265, 13137-42.
18. Perez RP, Hamilton TC and Ozols RF, 1990, Resistance to alkylaling agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther, 48, 19-27.
19. Timmer-Bosscha H, Hospers GA, Meijer C, et al. 1989, Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst, 81, 1069-75.
20. Deutsch DG and Mertz ET, 1970, Plasminogen: purification from human plasma by affinity chromatography. Science, 170, 1095-96.
21. Ali-Osman F, Stein DE and Renwick, A, 1990, Glulathione content and glutathione transferase expression in 1,3-bis (2-chloroethyl)-1-nitrosourea resistant human malignant astrocytoma cell lines. Cancer Res, 50, 6976-80.
22. Bradford M, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54.
23. Reich R, Thompson EW, Iwamoto Y, et al. 1988, Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res, 48, 3307-12.
24. Mignatti P, Robbins E and Rifkin DB, 1986, Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47, 487-98.
25. Sawaya R and Highsmith R, 1988, Plasminogen activator activity and molecular weight patterns in human brain tumors. J Neurosurg, 68, 73-79.
26. Landau BJ, Kwaan HC, Verrusio EN and Brem SS, 1994, Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res, 54, 1105-8.
27. Shinkai T, Saijo N, Tominaga K, et al. 1985, Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep, 69, 945-51.
28. Buckner JC, Brown LD, Kugler JW, et al. 1995, Phase II evaluation of recombinant interferon alpha and BCNlJ in recurrent glioma. J Neurosurg, 82, 430-5.
29. Barry MA, Behnke CA and Eastman A, 1990, Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol, 40, 2353-62.
30. Eastman A, 1990, Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 2, 275-80.
31. Miyashita T and Reed JC, 1993, Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81, 151-57.